What is the recommended evaluation and management strategy for eosinophilia, including workup, treatment thresholds, and therapeutic options?

Management of Eosinophilia

Begin with a thorough assessment to distinguish secondary (reactive) from primary (clonal) eosinophilia, prioritizing exclusion of parasitic infections, drug reactions, and organ-specific eosinophilic diseases before pursuing hematologic evaluation, because the treatment strategy and prognosis depend entirely on the underlying cause. 1, 2

Initial Diagnostic Approach

Define the Degree of Eosinophilia

• Hypereosinophilia is defined as a peripheral blood eosinophil count >1.5 × 10⁹/L, which warrants systematic evaluation because this threshold is associated with potential end-organ damage. 2, 3
• Mild eosinophilia (<1.5 × 10⁹/L) without symptoms or organ involvement may be managed with close observation and serial monitoring rather than immediate extensive workup. 2

Exclude Secondary Causes First

• Parasitic infections are the most common cause globally and must be ruled out through detailed travel history, fresh water exposure (lakes, slow-moving rivers), and serologic testing for schistosomiasis, strongyloidiasis, and other helminths. 1

• Serology for schistosomiasis becomes positive at 4–8 weeks post-exposure; concentrated stool microscopy has low sensitivity, so negative stool samples do not exclude infection. 1

• For strongyloidiasis, faecal PCR and specialized stool culture are more sensitive than standard microscopy. 1

• Drug-induced eosinophilia is frequently accompanied by pulmonary or hepatic involvement; obtain a comprehensive medication history including over-the-counter drugs, supplements, and recent antibiotic courses (especially β-lactams such as sulbactam/cefoperazone, meropenem, and tazobactam/piperacillin). 1, 4

• Drug rash with eosinophilia and systemic symptoms (DRESS) carries 6.9% mortality and is most commonly triggered by allopurinol, lamotrigine, and vancomycin; early recognition and drug withdrawal are essential. 5

• Organ-specific eosinophilic diseases include eosinophilic esophagitis, eosinophilic pneumonias, Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis), and eosinophilic gastroenteritides; assess for dysphagia, respiratory symptoms, asthma, sinusitis, abdominal pain, and skin manifestations. 1, 3

Evaluation for Primary (Clonal) Eosinophilia

When to Suspect Clonal Disease

• Persistent hypereosinophilia (>1.5 × 10⁹/L) after exclusion of secondary causes, especially when accompanied by splenomegaly, constitutional symptoms (fever, weight loss, night sweats), or evidence of organ damage (cardiac, pulmonary, gastrointestinal, dermatologic), mandates hematologic evaluation. 2, 6
• Marked eosinophilia (>20 × 10⁹/L) with multisystem involvement (pulmonary infiltrates, gastrointestinal inflammation, cutaneous ulcers) should raise immediate suspicion for myeloid neoplasm with tyrosine kinase fusion. 6

Essential Hematologic Workup

• Bone marrow examination with morphologic review, standard cytogenetics, and fluorescence in situ hybridization (FISH) to detect clonal markers. 2, 7
• Molecular testing for PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2 rearrangements is critical because these define specific WHO-recognized myeloid/lymphoid neoplasms with eosinophilia that are exquisitely responsive to targeted therapy. 2, 6
• Next-generation sequencing gene panels and flow immunophenotyping to identify acute or chronic hematolymphoid neoplasms. 2
• T-cell clonality studies to detect lymphocyte-variant hypereosinophilia, which is driven by an aberrant T-cell clone producing IL-5 and represents a reactive (not clonal) eosinophilia. 2

Treatment Strategies by Etiology

PDGFRA or PDGFRB-Rearranged Myeloid Neoplasms

• Imatinib is the definitive treatment for PDGFRA- or PDGFRB-rearranged disease, initiated at 400 mg daily (may be reduced to 100–200 mg daily after response), because these patients achieve rapid and dramatic hematologic and clinical remission within 2 weeks. 2, 6
• Early molecular testing and prompt imatinib initiation prevent irreversible organ damage (cardiac fibrosis, gastrointestinal ulceration, pulmonary infiltrates). 6

Lymphocyte-Variant Hypereosinophilia and Idiopathic HES

• Corticosteroids are first-line therapy for lymphocyte-variant hypereosinophilia and idiopathic hypereosinophilic syndrome (HES), typically prednisone 1 mg/kg/day (maximum 60 mg) with gradual taper based on clinical and laboratory response. 2
• Hydroxyurea and interferon-α are effective as initial treatment or in steroid-refractory cases of idiopathic HES. 2
• Mepolizumab (anti-IL-5 monoclonal antibody) is FDA-approved for idiopathic HES and provides a steroid-sparing option for patients requiring long-term therapy. 2
• Benralizumab (anti-IL-5 receptor antibody) is under active investigation and may offer additional therapeutic options. 2

Organ-Specific Eosinophilic Diseases

Eosinophilic Esophagitis

• Topical corticosteroids (fluticasone or budesonide swallowed rather than inhaled) achieve histological remission in 64.9% of patients and are the most effective first-line pharmacologic therapy. 8, 9
• Administer by spraying metered-dose inhaler into the mouth with lips sealed around the device, then avoid eating, drinking, or rinsing for 30 minutes; continue for 8–12 weeks before endoscopic reassessment. 9
• Proton pump inhibitors (omeprazole 20 mg twice daily) achieve histological response in 41.7% and are particularly useful when GERD coexists. 8
• Endoscopy with biopsy while on treatment is mandatory because symptoms do not reliably correlate with histological activity in ~41% of patients; histological remission is defined as <15 eosinophils per high-power field. 8, 9
• Long-term maintenance therapy is necessary because relapse rates are high after discontinuation; continue the agent that achieved remission indefinitely to prevent stricture formation. 8, 9

Schistosomiasis (Intestinal/Hepatosplenic)

• Praziquantel is the treatment of choice for schistosomiasis; dosing and duration depend on species (S. mansoni, S. japonicum, S. intercalatum, S. guineensis, S. mekongi). 1
• Serology remains positive for many years after successful treatment and cannot be used to assess cure; follow-up relies on clinical improvement and resolution of eosinophilia. 1
• Hepatosplenic schistosomiasis with portal hypertension requires abdominal ultrasound and upper gastrointestinal endoscopy to assess for esophageal varices. 1

Strongyloidiasis

• Ivermectin is first-line therapy for strongyloidiasis; in hyperinfection syndrome, urgent stool and sputum microscopy are required because mortality is high. 1
• Corticosteroids must be avoided until parasitic infection is definitively excluded, as they can precipitate fatal hyperinfection syndrome in undiagnosed strongyloidiasis. 1

Loa loa (African Eye Worm)

• Do not treat with diethylcarbamazine (DEC) if microfilariae are seen in blood at levels >1000/mL, because DEC causes fatal encephalopathy in high-level microfilaraemia. 1
• Use corticosteroids with albendazole to reduce microfilaria load below 1000/mL before definitive treatment with DEC; always discuss with a specialist tropical medicine or parasitology team. 1

Monitoring for End-Organ Damage

Cardiac Evaluation

• Eosinophil-mediated cardiac damage (endomyocardial fibrosis, restrictive cardiomyopathy, thrombosis) is the leading cause of morbidity and mortality in hypereosinophilic syndromes. 3
• Obtain baseline echocardiography, ECG, and cardiac biomarkers (troponin, BNP) in all patients with hypereosinophilia >1.5 × 10⁹/L, especially if symptomatic or if eosinophilia has been present for >6 months. 3

Pulmonary, Gastrointestinal, and Dermatologic Assessment

• Chest radiograph or CT to detect pulmonary infiltrates, pleural effusion, or cavitation. 1
• Abdominal imaging (ultrasound or CT) if gastrointestinal symptoms, hepatosplenomegaly, or elevated liver enzymes are present. 1, 6
• Dermatologic examination for cutaneous ulcers, urticaria, or angioedema, which may indicate clonal disease or drug hypersensitivity. 6, 5

Critical Pitfalls to Avoid

• Do not delay parasitic workup in travelers or migrants, even if exposure history is unclear, because schistosomiasis and strongyloidiasis are common and treatable causes of persistent eosinophilia. 1
• Do not initiate corticosteroids before excluding strongyloidiasis, as this can precipitate fatal hyperinfection syndrome. 1
• Do not assume symptom resolution equals disease control in eosinophilic esophagitis; mandatory endoscopic reassessment is essential because histological activity persists in many asymptomatic patients. 8, 9
• Do not miss PDGFRA/PDGFRB-rearranged disease by failing to perform molecular testing in persistent hypereosinophilia, because these patients achieve dramatic remission with imatinib and suffer irreversible organ damage without treatment. 2, 6
• Do not use allergy testing (skin-prick, specific IgE) to guide dietary elimination in eosinophilic esophagitis, as its predictive value is only ~45.5% in this non-IgE-mediated disease. 8

Referral Recommendations

• Refer to hematology for persistent hypereosinophilia (>1.5 × 10⁹/L) without identified secondary cause, or when clonal disease is suspected based on splenomegaly, constitutional symptoms, or multisystem involvement. 2, 10
• Refer to tropical medicine or infectious disease for complex parasitic infections (Loa loa, disseminated strongyloidiasis) or when serologic interpretation is uncertain. 1
• Refer to gastroenterology for suspected eosinophilic esophagitis or gastrointestinal eosinophilic disorders requiring endoscopic evaluation and biopsy. 8, 9
• Establish multidisciplinary team involvement (hematology, allergy, dermatology, gastroenterology, pulmonary, infectious disease) for patients with unexplained hypereosinophilia or those not responding to initial therapy, because the overlap in symptoms and risk of irreversible organ damage warrant specialized evaluation. 10